Sansevera v. EI DuPont De Nemours & Co., Inc.

859 F. Supp. 106, 18 Employee Benefits Cas. (BNA) 2177, 1994 U.S. Dist. LEXIS 10907, 1994 WL 409653
CourtDistrict Court, S.D. New York
DecidedAugust 4, 1994
Docket92 CIV. 6365 (MGC)
StatusPublished
Cited by22 cases

This text of 859 F. Supp. 106 (Sansevera v. EI DuPont De Nemours & Co., Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sansevera v. EI DuPont De Nemours & Co., Inc., 859 F. Supp. 106, 18 Employee Benefits Cas. (BNA) 2177, 1994 U.S. Dist. LEXIS 10907, 1994 WL 409653 (S.D.N.Y. 1994).

Opinion

OPINION AND ORDER

CEDARBAUM, District Judge.

Plaintiff Richard Sansevera, a former employee of DuPont Imaging Systems, a subsidiary of defendant E.I. DuPont de Nemours & Co., sues defendant pursuant to § 502 of the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1132(a)(1)(B). Sansevera, who suffers from Chronic Fatigue Syndrome (“CFS”), seeks a declaratory judgment that he is eligible for benefits under DuPont’s Total and Permanent Disability Income Plan, an award of benefits past due from August 2, 1990 to the present plus interest, and an order enjoining DuPont from improperly denying him benefits in the future. In addition, Sansev-era seeks to recover attorney’s fees and costs, pursuant to 29 U.S.C. § 1132(g)(1). DuPont’s motion to strike Sansevera’s request for punitive damages was granted by oral opinion in open court on February 26, *108 1993. (Tr. at 13.) DuPont and Sansevera now cross-move for summary judgment.

For the reasons discussed below, DuPont’s motion for summary judgment is denied, and Sansevera’s motion for summary judgment is granted in part and denied in part.

The Facts

The following facts, except where noted, are undisputed. On October 13, 1988, San-severa, at the age of forty-five, began working as a Director of Marketing and Sales for Crosfield Electronics. (Def. 3(g) Stmt, at 3, ¶¶ 8, 9.) In February of 1990, Sansevera became ill. He reported symptoms of “terrible fatigue, dizziness, nausea, swollen glands, a low grade fever, and the inability to get out of bed, walk around or generally function.” (PI. 3(g) Stmt, at 3, ¶ 3.) He began receiving short-term disability benefits from Crosfield on February 2, 1990, and has since been diagnosed as suffering from CFS. (Id. ¶ 3, 4.) While Sansevera was on disability leave, Crosfield was acquired by DuPont. On July 1, 1990, Sansevera became an employee of DuPont Imaging Systems, and began receiving benefits equivalent to his full salary under DuPont’s short-term disability plan. (Def. 3(g) Stmt, at 3-4, ¶¶ 12, 15, 16.) On August 2,1990, Sansevera’s six-month short-term disability period expired, at which time he applied to receive benefits under DuPont’s Total and Permanent Disability Income Plan (the “Plan”). He continued to receive his full salary until August 31, 1990, when he was officially terminated. (PL 3(g) Stmt, at 4, 18.)

According to the Plan, determinations regarding eligibility for benefits are made by the Board of Benefits and Pensions (the “Board”). (Pl.Ex. 11, HVIII(B).) The Plan provides that “[a]n individual shall be considered ‘totally and permanently disabled’ if the [Board] finds that he is totally disabled by injuries or disease and presumably will be totally and permanently prevented from pursuing any gainful occupation....” (Id. ¶ 11(E).) In 1990, an initial review of applications for benefits under the Plan was conducted by the Case Determination Committee. (Hay Aff. ¶ 7.) This Committee was replaced in January of 1991 by a two-person initial review committee, comprised of Dr. Alan J. Hay, then Assistant Corporate Medical Director for DuPont and medical adviser to the Case Determination Committee, and George Hollodick, then a manager in the Pensions, Compensation and Benefits area. (Hay Aff. ¶ 7.) According to Herbert Watson, Benefits Consultant for DuPont, since Mr. Hollodick is not a doctor, his role was merely to “sign[ ] off’ on Dr. Hay’s determinations regarding medical eligibility. (Watson Dep. at 51-52.)

In accordance with standard procedure, after Sansevera applied to receive benefits under the Plan, he was examined by a DuPont physician, Dr. Michele Deltieure. In a report dated August 29, 1990, Dr. Deltieure stated that Sansevera had been diagnosed with CFS, but that his physical condition was within normal limits and that his prognosis was “good.” (Pl.Ex. 13, ¶¶4, 5.) Dr. Hay, as medical adviser to the Case Determination Committee, was responsible for reviewing the medical information submitted in support of Sansevera’s claim and making recommendations to the Committee concerning his eligibility. (Hay Aff. ¶ 3.) After reviewing Dr. Deltieure’s report and another report which showed that a brain scan had revealed no abnormalities, Dr. Hay concluded: “Prognosis for life is good. Prognosis for change in behavior is uncertain. Prognosis for performing the activities of work is good.” (PI. Ex. 13.) In his affidavit, Dr. Hay states that this conclusion was also supported by literature on CFS which suggested that “patients seemed to improve over time,” and the fact that no medical study has proven that CFS is a permanent condition. (Hay Aff. ¶ 10.)

In a letter dated September 18, 1990, before the Case Determination Committee had met to review his application, Sansevera was notified that “[t]he initial determination was that you did not qualify for coverage under the DuPont Total and Permanent Disability Plan.” (Pl.Ex. 17.) DuPont contends that this letter was sent by mistake, and that Sansevera’s application was given full and fair consideration by the Committee. (Def. 3(g) Counter-Stmt. ¶ 9.) The Committee reviewed Sansevera’s application in October of 1990, and tabled its decision “pending the *109 results of an independent third-party evaluation of his physical condition.” (PL Ex. 18.) No such evaluation was ever undertaken. Instead, Dr. Hay recommended that Sansev-era be evaluated by a psychiatrist to determine if he could qualify for benefits under the Plan on the basis of his depression. (Hay Aff. ¶ 12.) Dr. Daniel W. Schwartz, a forensic psychiatrist, examined Sansevera, and in a letter dated December 8, 1990, concluded that he “is not suffering any impairment of his ability as marketing manager as a result of mental disease or defect.” (Pl.Ex. 19.) Dr. Schwartz also noted that “[t]he physical symptoms themselves of [CFS] are enough to render such impairment.” (Id.)

In support of his application, Sansevera submitted to the Committee an evaluation by Dr. Susan M. Levine, who had had extensive experience with CFS patients and, in 1990, was one of thirteen physicians appointed to serve on a committee organized by the Center for Disease Control to study CFS. (Levine Aff. ¶¶ 2, 3.) In a letter dated January 25, 1991, Dr. Levine reported that Sansev-era’s “symptoms, physical exam and laboratory studies, in addition to the lack of any evidence for any other concurrent illness point[] to a firm diagnosis of the Chronic Fatigue Syndrome.” (Pl.Ex. 23 at 1-2.) She concluded that Sansevera “remains totally and permanently disabled.” (Id. at 2.)

Sansevera also submitted a report dated January 8, 1991, by Dr. R.J. Romano, who had been treating him since March of 1990. Dr. Romano diagnosed Sansevera as suffering from CFS, and reported that his “prognosis for recovery is guarded and I believe that he will suffer from this condition for a prolonged period of time which means multiple years, if not for the rest of his life.” (Pl.Ex. 24 at 2.) In response to a questionnaire sent by DuPont, which asked, “Are [Sansevera’s impairments] temporary, or are they expected to be permanent?,” Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Callas v. S&P Global Inc.
S.D. New York, 2022
Benjamin v. Oxford Health Ins., Inc.
355 F. Supp. 3d 131 (D. Connecticut, 2019)
Stolarik v. N.Y. Times Co.
323 F. Supp. 3d 523 (S.D. Illinois, 2018)
Munnelly v. Fordham Univ. Faculty
316 F. Supp. 3d 714 (S.D. Illinois, 2018)
Mahoney v. J.J. Weiser & Co.
646 F. Supp. 2d 582 (S.D. New York, 2009)
Magee v. Metropolitan Life Insurance
632 F. Supp. 2d 308 (S.D. New York, 2009)
Curry v. American International Group, Inc. Plan No. 502
579 F. Supp. 2d 413 (S.D. New York, 2008)
Krauss v. Oxford Health Plans, Inc.
418 F. Supp. 2d 416 (S.D. New York, 2005)
Edwards v. Akzo Nobel, Inc.
193 F. Supp. 2d 680 (W.D. New York, 2001)
Martin v. E.I. DuPont De Nemours & Co.
999 F. Supp. 416 (W.D. New York, 1998)
Darling v. E.I. DuPont De Nemours & Co.
952 F. Supp. 162 (W.D. New York, 1997)
Whitney v. Empire Blue Cross and Blue Shield
920 F. Supp. 477 (S.D. New York, 1996)
Citrin v. Erikson
918 F. Supp. 792 (S.D. New York, 1996)
Mitchell v. Eastman Kodak Co.
910 F. Supp. 1044 (M.D. Pennsylvania, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
859 F. Supp. 106, 18 Employee Benefits Cas. (BNA) 2177, 1994 U.S. Dist. LEXIS 10907, 1994 WL 409653, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sansevera-v-ei-dupont-de-nemours-co-inc-nysd-1994.